Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
07:25am, Thursday, 02'nd May 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
10:46am, Tuesday, 30'th Apr 2024
Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
07:30am, Thursday, 18'th Apr 2024
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
08:30am, Thursday, 04'th Apr 2024
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Moderna shares fall after judge sides with Arbutus in patent fight
02:02pm, Wednesday, 03'rd Apr 2024
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Friday, 08'th Mar 2024
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
01:05pm, Thursday, 29'th Feb 2024
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
09:41am, Thursday, 29'th Feb 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
07:30am, Thursday, 29'th Feb 2024
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 15'th Feb 2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
07:30am, Monday, 08'th Jan 2024
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Wednesday, 08'th Nov 2023
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript
11:06am, Tuesday, 07'th Nov 2023
Arbutus Biopharma Corporation. (NASDAQ:ABUS ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director Dav
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07:30am, Tuesday, 07'th Nov 2023
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-s
